The STAMPEDE Trial (MRC PR08, CRUK/06/019) has recruited men starting first-line long-term hormone therapy (HT) for the first time for prostate cancer with or without metastases. The STAMPEDE population therefore includes a cohort of men with newly diagnosed nonmetastatic (M0) disease that is either high risk localized or node positive (N+); approximately 40% of trial entrants have no metastases. The trial uses a multiarm, multistage design to test the addition of further treatments to HT-based therapy, including docetaxel, zoledronic acid, celecoxib, abiraterone acetate, enzalutamide, and, only in patients with newly diagnosed metastatic (M1) disease, local radiotherapy (RT). Research arms have recruited at overlapping times, but, throughout, the control arm has consistently been use of HT, with RT where appropriate.
1-8